medRxiv preprint doi: https://doi.org/10.1101/2021.01.24.21250424; this version posted September 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

	porporaity.	
It is made available under	a CC-BY-NC 4.0 Int	ernational license .

1	Genome-wide meta-analysis of pneumonia suggests a role for mucin
2	biology and provides novel drug repurposing opportunities
3	
4 5	William R. Reay ^{1,2} , Michael P. Geaghan ^{1,2} , 23andMe Research Team ^{3†} , Murray J. Cairns ^{1,2*}
6	¹ School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, The
7	University of Newcastle, Callaghan, NSW, 2308, Australia
8	² Hunter Medical Research Institute, Newcastle, NSW, 2305, Australia
9	³ 23andMe Inc., Sunnyvale, CA, 94086, United States of America
10	
11	[†] A list of authors and their affiliations appears at the end of the paper
12	
13	*To whom correspondence should be addressed:
14	Professor Murray Cairns, Medical Sciences Building, University Drive, Callaghan, NSW
15	2308, Australia
16	Email: Murray.cairns@newcastle.edu.au, Phone: +61 02 4921 8670
17	
18	ABSTRACT
19	Pneumonia remains one of the leading causes of death worldwide, particularly amongst the
20	elderly and young children. We performed a genome-wide meta-analysis of lifetime
21	pneumonia diagnosis (N=266,277), that encompassed the largest collection of cases published
22	to date. Genome-wide significant associations with pneumonia were uncovered for the first
23	time beyond the major histocompatibility complex region, with three novel loci, including a

time beyond the major histocompatibility complex region, with three novel loci, including a signal fine-mapped to a cluster of mucin genes. Moreover, we demonstrated evidence of a polygenic effect of common and low frequency pneumonia associated variation impacting several other mucin genes and *O*-glycosylation, further suggesting a role for these processes in pneumonia pathophysiology. The pneumonia GWAS was then leveraged to identify drug

pneumonia pathophysiology. The pneumonia GWAS was then leveraged to identify drug repurposing opportunities, including evidence that supports the use of lipid modifying agents in the prevention and treatment of the disorder. We also propose how polygenic risk could be utilised for precision drug repurposing through pneumonia risk scores constructed using variants mapped to pathways with known drug targets. In summary, we provide novel insights into the genetic architecture of pneumonia susceptibility, with future study warranted to functionally interrogate novel association signals and evaluate the suitability of the compounds NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 INTRODUCTION

Pneumonia is characterised as an acute infection of the lung, with fluid filled alveoli and 36 37 resultant restriction of oxygen intake being a key hallmark of its pathophysiology. There are a number of mechanisms known to cause pneumonia, however, bacterial or viral infection are 38 39 the most common aetiologies¹. Pharmacological intervention in pneumonia treatment is largely 40 dependent on the infection source – for instance, bacterial induced pneumonia is treated with antibiotics. Yearly mortality rates worldwide from pneumonia remain high, even in the 41 developed world where access to antibiotics and routine hospital care is usually unrestricted^{2,3}. 42 43 This necessitates a greater understanding of the mechanisms involved in pneumonia 44 susceptibility and pathogenesis, which could be leveraged to identify novel treatments and 45 inform the repositioning of existing drugs.

46

47 There has been considerable work undertaken to identify host factors which influence the onset 48 and clinical course of pneumonia. Twin-based estimates of pneumonia heritability are still 49 lacking, however, the heritability of death due to infections disease has been estimated as high 50 as 40%, although further study is required ⁴. There have also been few studies which have used 51 modern statistical genetics approaches to test for the existence of risk-increasing or protective 52 alleles associated with pneumonia with sufficient power for surpassing genome-wide 53 significance. Previously, a genome-wide association study of lifetime self-reported pneumonia 54 diagnosis was published using participants obtained by 23andMe Inc. that identified a significant signal in the major histocompatibility complex (MHC) region on chromosome six⁵. 55 56 We sought to increase statistical power to detect association signals by performing a genome-57 wide meta-analysis of self-reported pneumonia in the 23andMe cohort with SNP effects on a 58 clinically ascertained pneumonia phenotype from the FinnGen consortium. The genetic 59 architecture of pneumonia was further interrogated to identify novel risk genes and salient 60 biological pathways, along with an estimate of genetic correlation with clinically significant phenotypes. These data were then considered in light of drug repurposing and provided support 61 62 to a number of plausible repositioning opportunities.

- 63
- 64
- 65
- 66
- 67
- 68

69 **MATERIALS AND METHODS**

70

71 Genome-wide meta-analysis of pneumonia

The genome-wide meta-analysis was performed using two primary study cohorts from 72 73 23andMe Inc. and FinnGen (release 3), respectively, with full details of these cohorts and the 74 meta-analysis procedure detailed in the supplementary methods. Summary statistics for a self-75 reported pneumonia phenotype were obtained from 23andMe as outlined by Tian *et al.*⁵. This 76 self-reported phenotype was derived from an online survey of 23andMe customers about their 77 medical history. In the final GWAS after quality control (QC), there were 40600 cases and 78 90039 controls. In addition, summary statistics for pneumonia were downloaded from the third 79 release of the FinnGen database which combines genotype data from Finnish biobanks and 80 digital health record data from Finnish health registries. The pneumonia phenotype chosen was All pneumoniae (J10 pneumonia), for which 15771 cases and 119867 controls were available 81 for GWAS after QC. 82

83

84 The 23andMe and FinnGen summary statistics were meta-analysed using an inverse-variance weighted model with fixed effects as implemented by METAL version March 2011⁶. Firstly, 85 86 we meta-analysed common variants, defined as sites with allele frequency > 1% in both the 23andMe and FinnGen cohorts. Variants were retained if they were available in both summary 87 88 statistics and had an imputation quality that exceeded a minimum of 0.3 or a mean of 0.5 for 89 variants not physically genotyped, resulting in 6888413 sites with an effect size estimate from 90 the meta-analysis and a total sample size of 266277 individuals. Imputed rare variants available 91 in both studies were subjected to a stricter filtering threshold for imputation quality such that 92 only variants with a minimum imputation quality > 0.5 or a mean value > 0.7 were subjected 93 to meta-analysis, with 834366 low frequency variants considered. In both instances, we further 94 tested for heterogeneity between the contributing studies using Cochran's Q test. Genome-wide 95 summary statistics from the IVW meta-analysis were processed using the FUMA v1.3.6 (Functional Mapping and Annotation of Genome-Wide Association Studies) platform⁷. 96 Genome-wide significant variants were characterised using the traditional $P < 5 \times 10^{-8}$ 97 98 threshold, whilst suggestive significance was defined using a more lenient threshold of P < 1×10^{-5} . We utilised the default settings for defining independent significant SNPs ($r^2 \le 0.6$) 99 and lead SNPs ($r^2 \le 0.1$). The reference panel population for LD estimation was the UK 100 101 biobank release 2b 10k White British panel, with LD blocks within 250 kb of each other merged 102 into a single locus. We examined the effect of conditioning on two smoking GWAS via the

103 multi-trait-based conditional & joint analysis (mtCOJO) framework implemented in GCTA v 1.93.2 beta (Supplementary Methods)^{8,9}. For the MUC5AC lead SNP, we additionally 104 105 performed a phenome-wide association study using the IEUGWAS database version 3.7.0 (https://gwas.mrcieu.ac.uk/), reporting SNPs using a conventional phenome-wide significance 106 107 threshold of $P < 1 \ge 10^{-5}$. Given the most significant association in this database was a GWAS of adult-onset asthma 10 , we tested whether the association of SNPs proximal to MUC5AC was 108 109 driven by the same underlying causal variant, assuming a single causal variant, via the *coloc* 110 colocalisation methodology implemented in version 4 of the package ¹¹. We also sought to 111 replicate our results in two UK biobank (UKBB) pneumonia GWAS, specifically, a selfreported pneumonia phenotype performed in the automated GWAS pipeline by the MRC IEU 112 113 group (ukb-b-4533, https://gwas.mrcieu.ac.uk/datasets/ukb-b-4533/), as well as a phecode ICD-10 UKBB GWAS performed in an automated series of GWAS by the authors of the 114 SAIGE methodology (https://pheweb.org/UKB-SAIGE/pheno/480)¹². 115

116

117 Estimation of SNP-based heritability

118 SNP based heritability was computed using LD score regression (LDSR) with 1000 genomes 119 phase 3 LD scores and weights¹³. We converted the heritability estimate to the liability scale 120 assuming the population prevalence of pneumonia as that of pneumonia in the FinnGen dataset 121 (12.61%), as well as a more conservative estimate based on ICD-10 diagnosed pneumonia in 122 the UK biobank (UKBB) sample (3.20% - Supplementary Methods).

123

124 Finemapping genome-wide significant loci

125 We finemapped the three-novel genome-wide significant loci outside of the MHC region by 126 using a method which leverages asymptotic Bayes' factors (ABF) to estimate credible sets under the assumption of a single causal variant¹⁴. Specifically, we utilised Wakefield's method 127 128 to approximate ABFs assuming a prior variance of 0.2^2 , which reflects the belief that the 129 confidence intervals of estimated variant effect sizes expressed as odds ratios ranging from 130 around 0.68 to 1.48. Given that the posterior probability for causality of each variant is 131 proportional to its Bayes' factor, these can be summed until a prespecified probability (ρ) is reached, thus, constituting a ρ set of putative causal variants. In this study, we derived 95% 132 133 credible sets. A single causal variant was assumed such that we did not have to account for LD 134 between variants, which has been demonstrated to be problematic in finemapping studies 135 which prespecify more than one causal variant using references external to the GWAS like the 136 1000 genomes project panel¹⁵.

137 Gene-based and gene-set association

Common variant (MAF > 0.01) SNP-wise P values were aggregated at gene-level using 138 139 MAGMA v1.07b¹⁶, as described in the supplementary methods. The Bonferroni threshold for genic association was $P < 2.68 \times 10^{-6}$, accounting for the number of genes tested. Moreover, 140 141 gene-based P values were leveraged for gene-set association using 1379 hallmark and canonical gene-sets from the Molecular Signatures Database (MSigDB)¹⁷. Rare variants (MAF 142 143 < 0.01) were also aggregated at gene-level by leveraging the properties of the Cauchy 144 distribution (Supplementary Methods). Code for the Cauchy combination test was obtained 145 from (https://github.com/yaowuliu/ACAT) and outlined by Liu and Xie^{18,19}. The MAGMA approach for common variants accounts for dependency between P values by estimating their 146 147 covariance as a function of pairwise LD in a population sample - however, there are methodological challenges with this approach for rare variants and likely much larger samples 148 149 would be required for accurate estimation of dependency between rare variants, if any exists^{20,21}. Therefore, we employed Cauchy transformation to combine *P* values as it guards 150 151 against type I error inflation due to potential unknown covariance between rare variants 152 (Supplementary Methods). In addition, we constructed a model for rare variant gene-set 153 association analogous to the MAGMA approach for common variants that leverages gene-154 based Z values (probit transformation of P). The same collection of pathways from MSigDB were considered, with genic Z values regressed against a binary indicator of set membership 155 156 $(\beta_{\rm S})$, covaried for logarithmically transformed gene-length, and rare variant count per gene. A one-sided test was performed for β_s , such that the null hypothesis is $\beta_s = 0$ and the alternative 157 158 $\beta_{\rm S} > 0$. Only gene-sets with rare variants overlapping at least 5 genes were retained.

159

160 Transcriptome-wide association studies of pneumonia

161 A transcriptome-wide association study (TWAS) of pneumonia was performed using the 162 FUSION package²². We utilised GTEx v7 SNP weights from three tissues that would be 163 plausibly involved in the pathophysiology of pneumonia (whole blood, lung, and spleen). We corrected for the number of *cis*-heritable genes outside the MHC region for which a TWAS Z 164 165 could be calculated in each tissue (Supplementary Methods). For transcriptome-wide 166 significant genes, we tested whether the expression and pneumonia-associated signal displayed 167 statistical colocalisation as encompassed by the SNP weights with the *coloc* package as implemented by FUSION¹¹. In addition, we probabilistically finemapped transcriptome-wide 168 169 significant regions using the FOCUS approach to derive a credible set of putative causal genes, as described previously²³. We utilised the default Bernoulli prior ($p = 1 \ge 10^{-3}$) and chi-square 170

171 prior variance $(n\sigma^2 = 40)$ to approximate Bayes' factors for each gene, and thus, derive the 172 posterior inclusion probabilities (*PIP*) for each gene to be causal given its observed TWAS *Z*. 173

174

175 Genetic correlation and causal inference

176 We estimated genetic correlation between pneumonia and 180 high quality, European ancestry GWAS using LDSR as implemented by the LDhub application²⁴. For Bonferroni significant 177 genetic correlation estimates, we constructed a latent causal variable (LCV) model using the 178 179 most significant trait from each LDhub phenotypic category and pneumonia to evaluate evidence for genetic causality between traits, as outlined extensively elsewhere^{25–27}. A strong 180 estimate of the posterior genetic causality proportion (GCP) was defined as significantly 181 182 different from zero (one sided *t*-test) and an absolute GCP estimate > 0.6. Weak GCP estimates 183 close to zero for genetically correlated traits imply that their relationship is potentially mediated 184 by horizontal pleiotropy, whereby there are shared pathways, but the two traits do not likely 185 exhibit vertical pleiotropy by acting within the same pathway. We additionally evaluated 186 evidence for a causal relationship between HDL cholesterol and pneumonia by constructing a multivariable Mendelian randomisation (MR) model using the TwoSampleMR package²⁸. This 187 188 multivariable model leveraged genetic instrumental variables (IV) from three highly 189 biologically interconnected lipid traits (LDL, HDL, and triglycerides) and estimated the effects 190 of these IVs on the outcome conditioned on their association with the other two lipid classes²⁹. 191

192 Genetically informed drug repurposing

193 We implemented three strategies to propose drug repurposing candidates: i) single loci drug-194 gene matching, ii) genetic correlation and/or evidence of a putative causal relationship between 195 a biochemical trait that could be targeted by an approved drug, and iii) precision drug repurposing using the polygenic scoring orientated *pharmagenic enrichment score* (PES) 196 197 approach. Full details of these analyses are described in the supplementary methods. We 198 utilised a panel of 50 biochemical GWAS performed by the Neale lab from the UK biobank 199 which had high or medium confidence estimates of SNP heritability that were significantly 200 different from zero (http://www.nealelab.is/uk-biobank) and estimated genetic correlation and 201 the posterior mean GCP for trait pairs that survived Bonferroni correction. We sought to 202 replicate the results of the multivariable MR for the three lipid classes (LDL, HDL, and 203 Triglycerides) using the UK biobank GWAS. MR was then performed to evaluate further 204 evidence for a causal effect between gamma-glutamyltransferase (GGT) and pneumonia, as

well as triglycerides and pneumonia (univariable estimate). Specifically, we defined independent, non-palindromic genome-wide significant variants as IVs and constructed four MR models with differing underlying assumptions (two inverse-variance weighted estimators with fixed or multiplicative random effects, weighted median estimator, weighted mode estimator, and MR-Egger)^{30–33}. A series of sensitivity analyses to evaluate statistical evidence for confounding pleiotropy was then undertaken as outlined in the supplementary methods^{32–} ³⁵.

212

213 The PES framework is based on the postulation that an enrichment of genetic risk within a 214 biological pathway with known drug targets may be an impetus to repurpose a drug which 215 modulates that pathway for individuals who carry the high genetic load mapped to the pathway, as described elsewhere^{36,37}. Specifically, we identify druggable pathways with an enrichment 216 217 of common variant associations relative to the rest of the genes tested and construct pathway-218 based risk scores for these gene-sets (Supplementary Methods). We utilised the UK biobank 219 (UKBB) cohort to test the association between a pneumonia PES and pneumonia phenotypes 220 recorded for these participants^{38,39}. These analyses are described in detail in the supplementary 221 methods. Briefly, we retained 336,896 unrelated white British ancestry participants and 222 13,568,914 autosomal variants that survived a series quality control steps, including, 223 imputation quality filtering (INFO > 0.8), MAF $> 1 \times 10^{-4}$, call rate > 0.98, and filtering strong 224 deviations from the Hardy-Weinberg equilibrium. Self-reported pneumonia diagnosis and 225 ICD-10 codes from hospital inpatient records were used to construct the pneumonia phenotype 226 (Supplementary Methods). There were 10,540 individuals from the genotyped subset of the 227 cohort included in the PES calculation with a primary or secondary diagnosis using the ICD-228 10 primary or secondary diagnosis codes relevant to pneumonia. In the strict phenotype 229 definition, we defined cases as those satisfying ICD-10 criteria, and controls as all those who 230 did not have one of those codes recorded along with any individual who self-reported 231 pneumonia without a pneumonia ICD-10 code ($N_{Controls} = 320,213$). Individuals who self-232 reported pneumonia but were not assigned a relevant ICD-10 code were excluded from the 233 study cohort in this strict configuration. In the broad-phenotype definition, pneumonia cases 234 were individuals with a relevant ICD-10 code or a self-reported lifetime pneumonia diagnosis 235 (N = 15,138). In other words, the strict definition only included individuals with a pneumonia 236 ICD-10 code. The PES was then constructed using common, autosomal variants outside of the 237 MHC region mapped to genes in that pathway with PRsice2 assuming an additive model, with 238 further details provided in the supplementary methods⁴⁰. The P value threshold of including

variants in the PES was the same as what was used to identify the gene-set. A genome widePRS for pneumonia susceptibility was also constructed in an analogous fashion.

241

242 We explored the phenotypic relevance of pneumonia PES profiles using a random subset of 243 the UKBB (N \sim 10,000) for which a multiplex assay was performed to quantity immunoglobulin G (IgG) antibody response to a series of antigens for infectious agents 244 245 selected for study, as outlined elsewhere⁴¹. The two phenotypes of interest here were a binary 246 indicator of *seropositivity* for 14 infections with seroprevalence > 5% in our genotyped subset 247 of the cohort, and amongst seropositive individuals, a continuous measure of antibody response (mean fluorescence intensity) to each antigen for that infection - termed seroreactivity. The 248 249 correlation between PES or PRS and seroreactivity was assessed by linear regression, whilst logistic regression was utilised for seropositivity. Both models were covaried for sex, age, age², 250 251 ten SNP derived principal components, genotyping batch, and two QC metrics related to the antibody assay (Supplementary Methods). A heatmap of the regression t statistics was 252 constructed using the ComplexHeatmap package⁴² 253

254

255 **RESULTS**

256

257 Novel common and rare variant loci associated with pneumonia

258 We performed a genome-wide meta-analysis of pneumonia using common and rare (MAF < 259 0.01) overlapping variants from 23andMe and FinnGen release three, with 6,888,413 and 260 834,366 common and low frequency sites tested, respectively. We estimated the SNP based heritability as approximately 3.24% on the liability scale (Fig. 1b), using the incidence of 261 262 pneumonia in the FinnGen cohorts as the population prevalence (12.67%), although we 263 acknowledge the population prevalence of pneumonia is difficult to quantify. As a result, we 264 re-estimated h^2 using a more conservative population prevalence value based on phenotype 265 data from the UK biobank (3.20%), resulting in a lower estimate of $h^{2}_{SNP} = 0.0213$. The point estimate of SNP-based h^2 was higher in the 23andMe cohort. $h^2_{SNP} = 0.054$, although the 266 267 estimate was more precise in the meta-analysis than in 23andMe and FinnGen alone: $Z_{Meta} =$ 9.26, $Z_{23andMe} = 7.44$, and $Z_{FinnGen} = 4.12$. In line with previous comparisons between self-268 269 reported and clinically ascertained phenotypes, the heritability estimate was lower in FinnGen 270 than 23andMe. There was some evidence of test statistic inflation when visualised as a QQ plot 271 (Supplementary Figure 1), however, the proportion of the polygenic signal in the meta-analysis

attributed to model misspecification and/or confounding was around 11% (LDSR ratio = 0.1145), whilst the mean χ^2 was large enough to estimate heritability (1.11).

274

There were four common genomic loci that surpassed the conventional genome-wide 275 276 significance threshold ($P < 5 \ge 10^{-8}$, Table 1, Fig. 1a,c, Supplementary Fig. 2-5). The effect sizes of these common variant signals were small in accordance with expectation, with each 277 278 SNP increasing or decreasing the odds of pneumonia by around 5%. Unsurprisingly, the most 279 significant signal spanned the major histocompatibility complex (MHC) region, which has 280 been previously published as associated with pneumonia in the 23andMe cohort⁵. Due to the 281 complexity of this region, we define the MHC signal as a single locus, with the minor allele of the lead common SNP associated with a small reduction in the odds of pneumonia (OR = 0.94282 $[95\% \text{ CI: } 0.92, 0.96], P = 6.44 \times 10^{-13})$. The most significant novel common signal in this study 283 was a region located on chromosome 11, with the lead SNP (rs28624253) located upstream of 284 285 the MUC5AC gene that encodes a mucin protein, with three other genes that encode a mucin protein within 400 kilobases of the lead SNP MUC6, MUC2, and MUC5B. Importantly, 286 rs28624253 was similarly associated in the 23andMe ($P = 2.65 \times 10^{-6}$) and FinnGen (P = 3.42) 287 $x \ 10^{-6}$) cohorts and there was no appreciable evidence for differences in population structure 288 289 between the input GWAS driving this signal. Mucins are heavily glycosylated proteins that 290 play a number of important roles, particularly in relation to the maintenance of mucosal 291 barriers⁴³. Mucin genes are known the exhibit somewhat pervasive genomic complexity and 292 evidence of heterogeneity between populations, to ensure that this signal is not just an artefact 293 of this, we performed a phenome-wide association study of the lead SNP and found that this 294 variant was associated with only relevant phenotypes to pneumonia. Specifically, it was linked 295 to adult-onset asthma, self-reported regular cough and mucus, and eosinophil count at a conventional phenome-wide significance threshold ($P < 1 \ge 10^{-5}$). Given rs28624253 was 296 297 associated with adult-onset asthma at a more stringent level of genome-wide significance, we 298 tested whether the mucin signal observed for pneumonia and adult-onset asthma were driven 299 by the same underlying causal variant and found strong evidence to support this hypothesis 300 (posterior probability > 90%). We caution that this assumes the existence of a single causal 301 variant, which may be unrealistic given the complexity of this region. As we visualise in 302 supplementary figure 6, if one utilises a more conservative prior probability of a shared causal 303 variant than there is some evidence that there is a different underlying causal variant but that 304 the locus is still associated with both traits. It should also be noted that the odds increasing 305 allele for pneumonia (G) is perhaps counterintuitively associated with decreased risk of asthma,

which suggests a multifaceted biological mechanism which may be related to the role of mucinsin the airway.

The third most significant locus encompassed several genes including SAMD8, DUSP13, and VDAC2, whilst locus four was largely intergenic, with some variants overlapping longnoncoding RNAs with limited annotation information (Supplementary Text). There were also two loci that almost surpassed genome-wide significance; specifically, a locus physically mapped to the interleukin-6 receptor region (*IL6R* – lead SNP: rs12730036, $P = 5.61 \times 10^{-8}$), and a region on chromosome 12 where the lead SNP is mapped to an intron of TNFRSF1A, which encodes a tumour necrosis factor receptor (lead SNP: rs1800693, $P = 5.5 \times 10^{-8}$). We integrated functional genomic and annotation data to prioritise candidate genes from the novel genome-wide significant loci in this study, as described in the supplementary text. We found that genes in the non-MHC loci implicated by at least two lines of evidence were enriched in phenotypically relevant pathways such as mucus layer, lung fibrosis, and O-linked glycosylation of mucins (Supplementary Figure 5, Supplementary Text). Interestingly, despite the meta-analysis combining a self-reported phenotype with clinically ascertained pneumonia diagnoses, only the lead SNP in the MHC locus demonstrated any significant heterogeneity in the effect sizes between the two cohorts (Cochran's Q, $P_{\text{Het}} = 0.04$, Table 1, Supplementary Text, Supplementary Figure 7).

medRxiv preprint doi: https://doi.org/10.1101/2021.01.24.21250424; this version posted September 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .





373 Figure 1. Genome-wide meta-analysis of pneumonia susceptibility. (a) Manhattan plot of common variant GWAS for pneumonia, as is usual practice, each point is the -374 375 $\log_{10} P$ value of a variant for association with pneumonia, with the red dotted line indicative of genome-wide significance ($P < 5 \ge 10^{-8}$). Lead SNPs are highlighted and 376 377 labelled on the plot, except for the MHC locus which we denote as "MHC" due to its complexity. (b) Estimates of SNP-based heritability (h^2) on the liability scale for the 378 379 23andMe and FinnGen cohorts individually, as well as the using the inverse-variance 380 weighted effects meta-analysis of the two cohorts. The error bars represent the standard 381 error of h^2 . (c) Region plots for the three-novel genome-wide significant loci outside of 382 the MHC region, the LD for each variant with the lead SNP estimates from the 1000 383 genomes phase III European reference set was utilised to colour the points.

384

385 Table one: Lead SNPs within common genome-wide significant loci associated with 386 pneumonia

Lead SNP	Locus	EA/NEA	EAF	EAF	OR	95%	P _{GWAS}	P _{Het}
			(NFE)	(FIN)		CI		
rs9268966	MHC	G/A	0.26	0.33	0.94	0.92,	6.44e ⁻¹³	0.04
						0.96		
rs28624253	chr11:1110395-	G/A	0.37	0.41	1.05	1.04,	5.27e ⁻¹¹	0.44
	1232702					1.07		
rs10762653	chr10:76815686-	G/A	0.16	0.18	1.06	1.04,	2.70e ⁻⁹	0.61
	76993015					1.08		
rs264954	chr2:104056454-	T/C	0.46	0.45	0.96	0.95,	$4.44e^{-8}$	0.53
	104380545					0.98		

Common (MAF > 0.01) lead SNPs were defined as independent SNPs ($r^2 < 0.1$) within each genomic locus. 387

388 The effect allele (EA) and non-effect allele (NEA) was reported for this table such that the effect allele was the

389 minor allele. The effect allele frequency (EAF) is denoted in gnomAD v2.1.1 for non-Finish Europeans (NFE)

390 and Finns (FIN). All odds ratio and their respective confidence intervals were calculated relative to the EA.

391 Heterogeneity of effect between the 23 and Me and FinnGen cohorts was tested using Cochran's Q, with the P

392 value of that test reported here (P_{Het}) . Due to the complexity of locus 1 (MHC), we report only a single common

393 SNP for this locus. Locus coordinates in in hg19 assembly.

394

395 The novel genome-wide significant loci outside the MHC region were finemapped to estimate a 95% credible set of plausible causal variants assuming a single causal variant in each region 396 397 (Supplementary Tables 1-3). The variants encompassed by the 95% credible set for the

398 rs28624253 locus were all proximally upstream/downstream of MUC5AC, or within the gene 399 itself, supporting the relevance of this mucin gene for that association signal. The second most 400 significant novel pneumonia associated locus discovered in this study (rs10762653 lead SNP) had a smaller credible set, with the lead SNP having a considerably high posterior probability 401 402 than the remaining credible set SNPs (PP = 0.676). Interestingly, the lead SNP for this locus 403 has low estimated LD with other proximal genome-wide significant SNPs (Fig 1c), suggesting 404 the existence of several causal variants that cannot be accounted for by this method. Finally, 405 the intergenic region spanned by the third novel genome-wide significant locus yielded a large 406 credible set of over 200 variants and, as a result, further functional interrogation is required to 407 mechanistically interpret this locus.

408

409 Smoking status was not included as a covariate in the respective GWAS meta-analysed, and 410 thus, we sought to investigate whether genetic variants associated with smoking may confound our findings in this GWAS. Specifically, we genetically conditioned common variant 411 412 associations on their effect size from a GWAS of smoking initiation and smoking heaviness 413 using mtCOJO⁸. The effect sizes of the lead SNPs from the novel genome-wide significant loci 414 were not greatly attenuated after conditioning on either of the smoking phenotypes and 415 remained genome wide significant, with the exception of the locus tagged by rs264954 (Conditioned on smoking initiation: $P = 7.15 \times 10^{-7}$; Conditioned on smoking heaviness: P =416 417 1.05×10^{-7}). Furthermore, there was a slight reduction in the SNP heritability estimate on the 418 liability scale, although this only amounted to a less than 0.5% difference after conditioning on 419 either smoking phenotype $-h^2_{\text{Conditioned on smoking initiation}} = 3.08\%, h^2_{\text{Conditioned on smoking heaviness}} =$ 420 2.95%.

421

422 We also uncovered a genome-wide significant association between a rare intergenic variant in 423 the MHC region and pneumonia - rs11962863, OR = 1.59 [95% CI: 1.44, 1.74], $P = 1.15 \times 10^{-10}$ 424 ⁹. This relatively large effect allele, however, did display statistically significant heterogeneity in its effect between the two cohorts ($P = 8.20 \times 10^{-5}$). This locus is considerably rarer in the 425 Finnish population (AF = 5.8×10^{-4}) than non-Finnish Europeans in gnomAD (AF = 2.9×10^{-5} 426 427 ³), which may account for its larger effect size in the FinnGen cohort. Due to the complexity 428 of recombination and linkage in the MHC locus, the functional consequences of this variant 429 remains difficult to interpret at an individual level without considering the local genomic 430 context of affected individuals, such as HLA type. We also detected six additional regions with

431 rare variants that surpassed suggestive significance for association with pneumonia (P < 1 x432 10^{-5} , Supplementary Table 4).

433

434 We sought to replicate our genome-wide significant and suggestively associated common loci 435 using two GWAS from the independent UK Biobank cohort - specifically, we utilised two 436 automated GWAS that encompassed a self-reported pneumonia phenotype ($N_{Case} = 6572$, 437 $N_{Controls} = 456,361$) and ICD-10 derived pneumonia diagnoses ($N_{Case} = 10,059$, $N_{Controls} =$ 398,538). We investigated both phenotyping approaches given our GWAS was a meta-analysis 438 439 of self-reported and clinically ascertained data. In the self-reported pneumonia UKBB GWAS, 440 we found that no SNPs replicated at genome-wide significance, however, the MUC5AC lead 441 SNP was nominally associated in the same direction ($\beta = 0.001$, $SE = 2.6 \times 10^{-3}$, P = 0.022), with the MHC lead SNP also was also nominally significant (P = 0.03) and the remaining two 442 lead SNPs demonstrated no significant evidence of replication. The ICD-10 phenotype GWAS 443 444 in the UKBB did not replicate any of our non-MHC genome-wide significant SNPs at even 445 nominal significance, although MHC SNPs were found to be nominally significant. It should 446 be noted that a limitation of both GWAS is that they focused only on either the self-reported 447 or clinically ascertained phenotype in the UKBB, meaning some controls plausibly would have 448 had pneumonia, and thus, decreasing power. Moreover, the effective sample sizes (Neff) of 449 these UKBB GWAS were markedly smaller than ours (177749 in the current discovery meta-450 analysis versus 25915 and 39246, respectively).

451

452 We also considered two very recent smaller sample-size pneumonia GWAS without publicly 453 available summary statistics to see if we could replicate their findings. Firstly, Chen et al. 454 performed a GWAS of pneumonia susceptibility and severity in the Vanderbilt University Biobank (BioVU, $N_{Case} = 8889$, $N_{Controls} = 60,767$, $N_{eff} = 31019$), European ancestry cohort)⁴⁴. 455 They found that a genome-wide significant common signal in Europeans associated with 456 457 pneumonia severity, with the lead SNP rs10786398 nominally associated in our meta-analysis: 458 $\beta = -0.029$, SE = 0.001, P = 2.5 x 10⁻⁴, whilst we were unable to replicate the significant rare-459 variant association signal from that study as the variant was not available in our analyses. Moreover, a meta-analysis of a smaller previous FinnGen release and ICD-10 ($N_{eff} = 94584$) 460 461 derived pneumonia in the UKBB found two genome-wide significant index SNPs in the 462 15q15.1 region that were directionally consistent in our analyses, although not statistically 463 significant, with a trend observed for rs76474922: $\beta = 0.025$, SE = 0.01, P = 0.08⁴⁵. The SNP-

464 based heritability estimate from that study also closely mirrored ours (3.3% on the liability465 scale), supporting the reliability of this study's estimate in a larger sample.

466

467 Gene and gene-set association further supports a role for mucin biology in pneumonia

468 We performed gene and gene-set association to investigate associations with pneumonia 469 beyond univariable SNP-phenotype relationships (Supplementary Tables 5,6). Six genes 470 outside of the MHC region were significant in the meta-analysis after the application of multiple-testing correction (MUC5AC, MUC5B, DUPD1, SAMD8, DUSP13, and TOX), all of 471 472 which were within genome-wide significant loci except for the TOX gene ($P = 1.26 \times 10^{-6}$), which plays a role in T cell persistence during response to a pathogen^{46,47}. Gene-set association 473 474 revealed a single gene-set for which its member genes were enriched with pneumonia 475 associated common variation relative to all other genes tested: Termination of O-glycan biosynthesis – $\beta = 0.89$, SE = 0.21, P = 1.05 x 10⁻⁵, q = 0.01. The strongest gene-based signal 476 477 in this pathway was accounted for by two mucin genes that span part of the genome-wide significant loci on chromosome 11 (MUC5AC, MUC2), whilst there were four other mucin 478 479 genes within this set that displayed a nominal gene-based association (P < 0.05) outside that 480 region (MUC15, MUC16, MUC12, and MUC17). The signal from this gene-set remained 481 relatively robust upon using a more conservative definition of the genic boundaries for SNP to gene annotation during gene-based association: $\beta = 0.66$, SE = 0.19, $P = 3.04 \times 10^{-4}$. Rare 482 variants were then subjected to gene-based association by leveraging the properties of the 483 484 Cauchy distribution, such that covariance between P values did not need to be estimated. No 485 genes surpassed Bonferroni correction, considering genes with at least two rare variants. The most significant gene found upon testing all genic rare variants was ZNF19, $P = 6.3 \times 10^{-5}$. 486 whilst *FREM1* was the top gene ($P = 8.16 \times 10^{-4}$) considering variants annotated as exonic only 487 488 (Supplementary Tables 7,8). Furthermore, we utilised the gene-based results to construct a 489 competitive rare variant gene-set association model and tested the same gene-sets as in the 490 common variant analyses (Supplementary Tables 9,10). While there were no gene-sets that 491 survived multiple-testing correction utilising all genic rare variants or those with only exonic 492 annotated sites, we found some support for B lymphocyte antigen response in the rare variant 493 architecture of pneumonia, as the most significant association from the rare variant model was with the *B* cell antigen receptor pathway - $\beta = 0.59$, SE = 0.19, $P = 7.7 \times 10^{-4}$. Interestingly, 494 495 there was also a nominal rare variant signal amongst pathways related to carbohydrate 496 metabolism (*Metabolism of carbohydrates* $-P = 6.22 \times 10^{-3}$, *Glycosaminoglycan degradation*

497 -P = 0.02) and glycosylation (*N-glycan biosynthesis* -P = 0.01), although these results must 498 be interpreted cautiously given, they do not survive multiple testing correction.

499

A transcriptome-wide association study was then undertaken to identify genes for which 500 501 genetically predicted expression was correlated with pneumonia susceptibility. We selected 502 SNP weights from three tissues which are plausibly biologically relevant to pneumonia 503 pathophysiology: lung, whole blood, and spleen. After applying Bonferroni correction to the 504 number of tests within each tissue outside the MHC individually, significant correlation was 505 observed between decreased predicted expression of VDAC2 and pneumonia (Z = -4.39, P =506 1.15 x 10⁻⁵, Supplementary Table 11) using spleen tissue as the prediction model. The 507 association between VDAC2 and pneumonia was also supported by SNP weights from the lung and whole blood, although these did not surpass the Bonferroni threshold: $P_{\text{Lung}} = 5.52 \text{ x } 10^{-4}$, 508 $P_{\text{Whole blood}} = 9.97 \text{ x } 10^{-4}$. We tested a related, but distinct hypothesis by assessing evidence for 509 510 colocalisation between the GWAS signal spanning VDAC2 and the SNP weights from the three 511 tissues utilised to construct the model of genetically predicted VDAC2 expression. 512 Colocalisation assumes a biologically conservative parameter of a single shared causal variant 513 that underlies the relationship between VDAC2 expression and pneumonia. We observed 514 heterogeneity between the three tissues, with moderately strong evidence of colocalisation between *VDAC2* expression and SNP weights from whole blood ($PP_{H4} = 0.848$), however, 515 516 using lung and spleen expression SNP weights there was no strong evidence (PP > 0.8) for any 517 of the five colocalisation hypotheses. In lung, there was evidence for an association between 518 *VDAC2* lung expression SNP weights and pneumonia ($PP_{H3} = 0.568$, $PP_{H4} = 0.363$), although 519 we were not able to clearly determine whether there were two independent SNPs driving the 520 association (H3) or a shared variant (H4). Interestingly, there was moderate support in the 521 model leveraging the spleen SNP expression weights that this signal was only associated with 522 pneumonia and not *VDAC2* expression ($PP_{H2} = 0.643$), which could be driven by the spleen 523 model of genetically regulated expression being somewhat less predictive ($R^2 = 0.038$, best linear unbiased prediction), than in blood ($R^2 = 0.1$, LASSO) and lung ($R^2 = 0.083$, elastic net), 524 525 respectively. Probabilistic finemapping of the marginal TWAS Z scores in the VDAC2 region 526 was then undertaken using a multi-tissue panel to assess evidence for whether VDAC2 is the 527 causal gene in this region. This locus was dense with genes, with 26 unique genes within the 528 90% credible set of causal genes. There was moderate evidence that VDAC2 was the most 529 probable causal gene at this locus given it had the largest absolute TWAS Z, the highest PIP 530 for an individual model from the adrenal gland (PIP = 0.279), and a relatively large cumulative

531 *PIP* for all 17 *VDAC2* models derived a variety of tissues that were finemapped (*PIP*_{Cumulative} 532 = 0.683). Further investigation is thus needed to refine this locus.

533

534 There were a number of other genes that trended towards surviving multiple-testing correction 535 in spleen and the other two tissues - including, PLD4 in spleen and STPG1 in lung. We 536 subjected genes that trended towards multiple testing correction (two orders of magnitude 537 above the Bonferroni threshold) to gene-set overrepresentation analysis to identify gene 538 ontologies enriched for these genes, with immune system process and immune response 539 overrepresented after multiple-testing correction, supporting the biological relevance of this 540 signal (Supplementary Table 12). For instance, downregulation of tumour necrosis factor 541 receptor gene TNFRS19 in lung trended towards correlation with pneumonia, Z = -3.44, P =5.78 x 10⁻⁴. 542

543

544 Pneumonia displays genetic correlation with clinically significant phenotypes

545 We estimated genetic correlation between pneumonia and 180 GWAS using LDSR, with a 546 significant non-zero estimate of genetic correlation obtained for twenty phenotypes after the application of multiple testing correction ($P < 2.78 \times 10^{-4}$, Supplementary Table 13, Fig. 2). 547 548 Interestingly, the most significant genetic correlation was found between pneumonia and insomnia ($r_g = 0.496$, SE = 0.075, $P = 3.55 \times 10^{-11}$), which supports previous observational data 549 that insomnia and reduced sleep duration increased the risk of developing pneumonia^{48,49}. In 550 addition, we uncovered significant genetic correlation with other clinically interesting 551 552 phenotypes including forced vital capacity ($r_g = -0.215$, SE = 0.0361, $P = 2.62 \times 10^{-9}$), obesity $(r_{\rm g} = 0.3023, SE = 0.0466, P = 9.15 \times 10^{-11})$, and HDL cholesterol $(r_{\rm g} = -0.2876, SE = 0.0664, P = 0.0664)$ 553 554 $P = 1.48 \text{ x } 10^{-5}$).





557 Figure 2. Estimates of genetic correlation between pneumonia and a panel of 558 GWAS that survive multiple testing correction. Each panel of the forest plot is the 559 estimate of genetic correlation by LD score regression (+/- its standard error, denoted 560 by the error bars). The dotted lines represent a genetic correlation of zero. Panels were 561 grouped by the phenotypic category of the trait subjected to LDSR.

562

563

A latent causal variable (LCV) model was then constructed for the most significantly 564 565 correlated trait-pairs from each phenotypic category that comprised the 180 GWAS tested for 566 genetic correlation. The LCV approach leverages the bivariate effect size distribution of SNPs in two GWAS and their LD scores to estimate a genetic causality proportion (GCP), 567 568 such that, evidence of partial genetic causality can be distinguished from genetic correlation. We found strong evidence ($|\widehat{GCP}| > 0.6$) for partial genetic causality of cigarettes per day and 569 570 HDL on pneumonia. Both posterior mean GCP estimates were significantly different from zero, however, the estimate of HDL \rightarrow pneumonia ($\widehat{GCP} = 0.758$, SE = 0.159, $P = 2.20 \times 10^{-10}$ 571 ¹¹) was more precise than that of cigarettes per day \rightarrow pneumonia ($\widehat{GCP} = 0.713$, SE = 0.225, 572 $P = 3.51 \times 10^{-3}$). The magnitude of the potential causal relationship between HDL and 573 574 pneumonia was further investigated using mendelian randomisation (MR). Given the 575 biological overlap between the genetic architecture of HDL and other lipid classes, we 576 constructed a multivariable MR model that conditioned HDL instrumental variables on their association with LDL cholesterol and triglycerides, obtaining the SNP-exposure estimates 577

578 from the Willer et al. global lipids genetics consortium paper, as has been outlined elsewhere ^{29,50}. There was no evidence of a causal effect of HDL (P = 0.65) or LDL (P = 0.47) 579 580 conditioned on the remaining lipid classes, although there was nominal evidence of a risk 581 increasing effect of triglycerides on pneumonia $-\beta = 0.058$, SE = 0.028, P = 0.035. These 582 data highlight the complexities of distinguishing between confounding pleiotropy and 583 evidence for causal relationships, with further work needed to resolve whether the 584 directionally disproportionate variant effect sizes for HDL \rightarrow pneumonia captured by the 585 LCV model represent a true evidence for a causal relationship or whether other factors like triglycerides may explain this relationship. In addition, the effect of other confounders like 586 587 BMI on these relationships cannot also be ruled out, although BMI did not show evidence of 588 a causal effect in the LCV model.

589

590 **Opportunities for drug repurposing by leveraging the genetic architecture of pneumonia** 591 We sought to interrogate the pneumonia GWAS to propose novel drug repurposing candidates 592 that could be useful to treat patients diagnosed with pneumonia more effectively. Firstly, we 593 utilised a very liberal approach which identified genes that were targeted by approved drugs 594 outside the MHC region physically mapped to loci associated with pneumonia at a minimum 595 of a suggestive significance threshold ($P \le 1 \ge 10^{-5}$). There were five such genes that displayed 596 a high confidence interaction with an approved pharmacological agent with a known 597 mechanism of action - IL6R, SCNN1A, ATP2B1, ERBB2, and STAT5B). For instance, 598 Tocilizumab is a monoclonal antibody that targets *IL6R* which has been suggested as a 599 repurposing opportunity to use for severe illness following SARS-CoV2 infection, although 600 results from randomised controlled trials have been mixed in terms of efficacy⁵¹. We examined these genes in the TWAS analyses, however, only *IL6R* was significantly *cis*-heritable in one 601 602 of the three tissues we utilised. Interestingly, there was a trend towards a correlation between 603 downregulation of *IL6R* and increased odds of pneumonia, which would not support the use of 604 anti-IL-6 receptor agents like tocilizumab – Z = -3.148, $P = 1.64 \times 10^{-3}$. In contrast, the lead 605 SNP and odds increasing allele of the *IL6R* locus in this GWAS has been associated with 606 increased *IL6R* levels in a protein quantitative trait loci study (pQTL), which would support 607 the efficacy of tocilizumab. We caution that the pQTL signal is in high LD with a missense 608 variant (rs2228145), and thus, antigen binding affinity may be altered to create an artefactual 609 pQTL association. These antigen-binding affinity related effects require further investigation, particularly in light of the phenomenon of the non-synonymous rs2228415 C allele displaying 610 correlation with increased protein abundance from the pQTL study⁵² but with decreased 611

612 expression via RNAseq derived eQTL estimates from whole blood by GTEx, along with 613 decreased CRP levels in the UK biobank, a well-characterised biomarker of IL-6 receptor (IL-614 6R) inhibition. Previous functional analyses of the rs2228145 non-synonymous allele have demonstrated that it likely impairs IL6 signalling, with increased expression of soluble 615 circulating IL-6R but downregulation of the membrane bound isoform⁵³. As a result, we 616 617 conclude that based on the genetic association alone that the anti-inflammatory effect of IL-6R 618 blockade may have a risk-increasing impact on pneumonia, although further work is required 619 to evaluate tocilizumab as a potential repurposing opportunity, particularly as its efficacy 620 would likely be dependent on its temporal application in the clinical course of the disease.

621

622 A panel of 50 metabolites and blood cell count phenotypes from the UK biobank (UKBB) with moderate to high confidence SNP-based heritability estimates were then tested for genetic 623 624 correlation with pneumonia (Supplementary Table 14). The concept underlying this is that if there is evidence of a relationship between a biochemical trait and pneumonia, then a drug 625 626 which modulates that trait in a risk-decreasing direction could be clinically useful, and thus, 627 repurposed for pneumonia. We found 13 biochemical traits from the UKBB panel that were 628 correlated with pneumonia after multiple-testing correction (Supplementary Table 15). The 629 most significant correlation was a positive genetic correlation with triglycerides, followed by 630 a positive correlation with glycaeted haemoglobin (HbA1c), which is interesting given 631 previous evidence that hyperglycaemia has a deleterious effect on lung function^{27,54}. The 632 correlation between HbA1c and pneumonia may not be necessarily driven by glycaemic 633 biology, particularly as HbA1c is strongly influenced by haematological factors, although we 634 did observe weak evidence for a positive correlation between glucose and pneumonia that does 635 not survive multiple testing correction (P = 0.01, Supplementary Table 15). It should be noted 636 that this UKBB sample is a larger sample size than the triglyceride GWAS subjected to LDSR 637 in the broad LDhub GWAS panel from earlier in the manuscript, and thus, the estimate is more 638 significant in this analysis. In addition, the HDL GWAS from the UKBB was not included due 639 to anomalous estimates of large standard error when considering its heritability estimate 640 (Supplementary Methods). There was only very weak evidence from the LCV model for a potential causal influence of triglycerides on pneumonia ($\widehat{GCP} = 0.465, SE = 0.226, P = 0.052$, 641 642 Figure 3a), although this broadly supports the results of the lipid multivariable MR described earlier in the manuscript that provided nominal evidence of a deleterious impact of increased 643 triglycerides. We attempted to replicate the earlier multivariable MR results using the LDL, 644

645 HDL, and triglyceride GWAS from the UK biobank as the exposure traits rather than the Willer et al. global lipids genetics consortium GWAS, with an analogous result that demonstrated an 646 647 odds-increasing effect of triglycerides but a non-significant effect of LDL or HDL cholesterol (Supplementary Table 16). We followed this up by estimating a univariable estimate of 648 649 triglycerides \rightarrow pneumonia, with a 5.4% mean increase in the odds of pneumonia per standard 650 deviation increase in triglycerides across the five MR methods utilised (Supplementary 651 Methods, Supplementary Table 17). The causal estimate was only statistically significant in 652 the case of the two IVW estimators: OR = 1.056 [95% CI: 1.01, 1.104], P = 0.017 (IVW 653 multiplicative random effects), however, the remaining models had relatively consistent point 654 estimates of the effect of triglycerides on pneumonia (Figure 3b). There was some nominal evidence of heterogeneity amongst IV exposure-outcome estimates (Q = 212.51, df = 168, P =655 0.01), however, the Egger intercept was not significantly different from – thus, we observed 656 657 no direct statistical evidence of confounding pleiotropy. As a result, these data suggest a 658 potential repurposing opportunity for drugs prescribed for hypertriglyceridemia, such as statins 659 and fibrates, with the caveat that the MR and LCV models from this study provide only 660 relatively weak to moderate support, particularly as the mean posterior GCP estimate was low, 661 and thus, genetic correlation could contaminate the MR estimate.

662

663 The remaining LCV models for biochemical traits genetically correlated with pneumonia did 664 not indicate any strong evidence of partial genetic causality, with the exception of a putative 665 effect of gamma-glutamyltransferase (GGT) on pneumonia that approximately reached the threshold for a strong point estimate of the GCP - $\widehat{GCP} = 0.59$, SE = 0.212, $P = 1.08 \times 10^{-4}$. 666 667 GGT is an enzyme that is commonly characterised as a biomarker of liver dysfunction, with 668 some evidence of an immunological role for this enzyme, as well as its involvement in alveolar 669 gas exchange. We further investigated this putative causal relationship by leveraging 207 independent SNPs associated with GGT ($P < 5 \ge 10^{-8}$) in the UK biobank as IVs – approximated 670 671 variance explained by IVs = 6.47%, *F*-statistic = 114.91. The five MR models implemented in 672 this study yielded a roughly similar effect size per SD increase in GGT that increased the odds of pneumonia (mean pneumonia OR per SD GGT increase = 1.055, Supplementary Table 18). 673 674 However, the estimates were not statistically significant, with the exception of the weighted median model (OR = 1.087 [95% CI: 1.01, 1.17], P = 0.025). There was evidence of 675 676 heterogeneity amongst the IV exposure-outcome effects, which may be indicative of confounding pleiotropy (Q = 301.87, df = 206, $P = 1.501 \times 10^{-5}$), although given the large 677

678 number of IVs observed heterogeneity is not a surprising phenomenon. Importantly, there was 679 no statistical evidence of pleiotropy from the intercept of the MR egger model. We caution that 680 statistical approaches to assess pleiotropy do not and cannot rule out a confounding influence on the MR estimate, and detailed biological annotation of the IVs would be warranted to 681 682 investigate this further. In summary, there may be a causal relationship between GGT and increased odds of pneumonia which could support inhibition of this enzyme as a treatment 683 684 target, with several GGT inhibitors under active development and explored for use in respiratory illness^{55,56}. 685

686

Furthermore, we compared the MR estimate of the effect of a standard deviation increase in 687 688 GGT and triglyceride concentration on the odds of pneumonia to an observational estimate from the UK biobank sample (Supplementary Methods). We found that the observational 689 690 association between a standard deviation increase in triglyceride concentration and pneumonia 691 was analogous to the univariable and multivariable MR estimates (OR = 1.059 [95% CI: 1.042, 1.076], $P = 2 \times 10^{-12}$), whilst the observed association between GGT and pneumonia was 692 693 stronger than the MR estimate, with each standard deviation associated with a 13.54% [95% 694 CI: 12.43%, 14.56%] increase in the odds of pneumonia amongst UK biobank participants. 695 Interestingly, these associations were also consistent amongst individuals in the UK biobank 696 with relatively lower risk of pneumonia, that is, non-smoking females aged 45 or younger at 697 time of assessment – triglycerides: OR = 1.335 [95% CI: 1.13, 1.555], $P = 2.67 \times 10^{-4}$, GGT: OR = 1.354 [95% CI: 1.161, 1.553], $P = 2.75 \times 10^{-5}$. These variables are extremely 698 699 heterogeneous and there are many potential confounders of the observed effect sizes, however, 700 it supports the inferred relationship from the LCV and MR models.



718 Figure 3. Investigating the potential utility of modulating biochemical traits as 719 drug repurposing opportunities for pneumonia. (a) Latent causal variable models 720 constructed between genetically correlated trait pairs after Bonferroni correction. Each point represents the genetic causality proportion, with the y axis denoting the precision 721 722 of the GCP estimate, that is, its Z score. The genetic correlation estimate between the 723 two traits was utilised to shade the points, with the larger points also indicative of a 724 larger GCP Z score. A positive GCP estimate is indicative of partial genetic causality 725 of the biochemical trait \rightarrow pneumonia, whilst a negative estimate represents the 726 converse. (b) A Mendelian randomisation (MR) analysis of the effect of genetically proxied gamma glutamyl-transferase (GGT) and triglycerides on the odds of 727 pneumonia. The scatter plot visualises the effect of each instrumental variable SNP on 728 729 GGT or triglycerides verses its effect on pneumonia, with the regression trend line the MR estimate from each of the five models implemented. Similarly, the forest plot 730 731 indicates the pneumonia odds ratio for each of the MR models, with the error bar 732 indicative of the 95% confidence intervals. The MR models were as follows: mode = 733 weighted mode estimator, median = weighted median estimator, IVW-FE = inversevariance weighted estimator with fixed effects, IVW-MRE = inverse-variance weighted 734 735 estimator with multiplicative random effects, Egger = MR-Egger regression.

- 736
- 737

738 Precision drug repurposing to treat pneumonia

739

740 We implemented the *pharmagenic enrichment score* (PES) approach to identify drug 741 repurposing candidates that could be targeted more precisely based on genetic risk^{27,37}. Briefly, the PES is a genetic risk score specifically within a biological pathway that is targeted by 742 743 approved drugs. The concept underlying the PES is that individuals with elevated genetic risk 744 within a particular druggable set of genes may benefit from a pharmacological agent that 745 modulates the pathway in question. Firstly, we identified five druggable pathways that 746 displayed an enrichment of the common variant genetic architecture of pneumonia at one of 747 four *P*-value thresholds for the inclusion of variants in the model (FDR < 0.05, Table 2, Supplementary Table 19, Supplementary Methods). These included two complement-related 748 749 pathways, *p53 signalling*, and *bile acid metabolism*.

750

	PES gene-set	P_{T}^{1}	Р	Example drug/nutraceutical
	P53 signalling pathway	0.05	2.13 x 10 ⁻⁸	Fostamatinib
	Lectin induced complement pathway	0.05	2.98 x 10 ⁻⁸	Human immunoglobulin
	Complement pathway	0.05	6.81 x 10 ⁻⁸	Zinc
	Bile acid metabolism	0.005	1 x 10 ⁻⁶	Atorvastatin
	RIG-I-like receptor signalling pathway	0.005	1.58 x 10 ⁻⁵	Etanercept
753	${}^{1}P_{\rm T} = P$ value threshold for variant inclusion	in the mo	del	

751 Table 2. Candidate druggable gene-sets that could be utilised to calculate pharmagenic

752 enrichment scores

754

 ${}^{1}P_{T} = P$ value threshold for variant inclusion in the model

755 There were a number of diverse compounds that targeted these pathways, with compounds 756 identified as repurposing candidates through testing whether there was a statistically significant overrepresentation of their targets in the gene-set, along with high confidence single drug-gene 757 758 interactions (Supplementary Tables 20,21). For instance, targets of the micronutrient zinc were 759 overrepresented amongst genes in the Complement pathway gene-set, supporting previous evidence that zinc can modulate complement activation ^{57,58}. 760

761

762 Characteristics of pneumonia pharmagenic enrichment scores

763

We investigated the properties of these five scores in the UKBB cohort. Interestingly, there 764 765 were no large correlations (all r < 0.07) between the PES and a genome-wide polygenic risk 766 score for pneumonia, which supports our hypothesis that pathway-based risk scores may 767 provide novel biological insights that are not encompassed by PRS constructed from variants 768 throughout the genome. Both the genome wide PRS and the PES profiles were not significantly 769 associated with pneumonia diagnosis (self-reported/clinically ascertained or clinically 770 ascertained only, Supplementary Tables 22,23, Supplementary Methods). This is perhaps not 771 surprising given the low SNP heritability of pneumonia and the heterogeneity of the phenotype 772 - however, we believe this does not preclude the relevance of PES at an individual level. For 773 instance, given the putative relationship between hypertriglyceridemia and increased odds of 774 pneumonia, as supported by this study, we tested the relationship between the pneumonia *Bile* 775 acid metabolism PES and measured triglycerides in the UKBB. There was a small but 776 significant positive correlation between the PES and triglyceride concentration – $\beta = 0.01$, SE = 0.002, $P = 1.69 \times 10^{-4}$, which was significant even after adjusting for statin use or using 777 triglyceride values as the outcome variable winsorized at three standard deviations above the 778

mean to guard against an excessive influence of outliers ($\beta = 0.01$, SE = 0.002, $P = 1.43 \times 10^{-7}$ ⁴). This relationship with triglycerides was not seen using genome wide PRS ($\beta = 1.57 \times 10^{-4}$, SE = 0.002, P = 0.93).

782

Associations between pneumonia pharmagenic enrichment scores and host susceptibility to
 infection

785

786 The relationship between PES, as a function of host genetic susceptibility to pneumonia, and 787 antibody response to infection was then assessed in a subset of the UKBB with these data 788 available and passing our genotyping QC thresholds (N = 6443). We implemented these 789 analyses given the host-immune response is directly relevant to pneumonia and if the PES 790 displays distinct correlations with antibody response compared to genome-wide pneumonia 791 PRS, it would emphasise the potential biological utility of the PES framework. Firstly, we 792 tested the association between each PES and antibody response to 28 antigens amongst 793 individuals with detectable levels of antibodies for 14 infections (seroreactivity, Fig. 4c, 794 Supplementary Table 24). The strongest relationship between a PES profile and seroreactivity 795 was a positive correlation between the Complement pathway PES and IgG response to the 796 major capsid protein VP1 of the BK polyomavirus, with each SD increase in the PES associated with a 0.05 (0.01) SD increase in antibody response, $P = 4.1 \times 10^{-4}$, which trended towards 797 798 surviving multiple testing correction (q = 0.07). There was no association between genome 799 wide PRS and IgG mediated response to this antigen. There were other nominally significant 800 correlations observed (Fig. 4a), with most of these correlations positive and potentially 801 indicative of an increased immune response. In addition, susceptibility to infection 802 (seropositivity) was also investigated (Supplementary Table 25). For instance, a nominal 803 association uncovered between RIG-I-like receptor signalling pathway and decreased odds of 804 herpes simplex virus-1 infection (OR = 0.93 per SD in score [95% CI: 0.87, 0.98], $P = 4 \times 10^{-10}$ 805 ³), whilst *Complement pathway* PES was nominally associated with increased odds of positive 806 *H. pylori* serostatus - OR = 1.07 per SD in score [95% CI: 1.01, 1.12], P = 0.02.

- 807
- 808
- 809
- 810
- 811
- 812



confidence intervals) per SD increase in the PES tested. The infections abbreviated are as follows: MCV = Merkel Cell Polyomavirus, JCV = Human Polyomavirus JCV, HSV = herpes simplex virus 1, HSV2 = herpes simplex virus 2, H. pylori = Helicobacter pylori. (b) IgG response (mean fluorescence intensity) to the major capsid protein VP1

843

844

845

846

847 of the BK polyomavirus in the 10th percentile (1st decile, denoted 1), 50th percentile (5th 848 decile, denoted 5), and 90th percentile (10th decile, denoted 10) of the complement 849 pathway PES amongst the genotyped subset of the UKBB subjected to antibody 850 screening included in our analyses. (c) Heatmap of the regression t statistic 851 (beta/standard error) for the correlation between each PES and PRS with respective IgG 852 response to antigens amongst individuals seropositive for that infection. Hierarchical 853 clustering was applied to the rows and columns using Pearson's correlation distance.

854

855 **DISCUSSION**

In this study, we uncovered the first significant association signals for lifetime pneumonia 856 857 susceptibility outside of the MHC region. Interestingly, there was also a novel low frequency variant in the MHC itself which reached genome-wide significant that confers a relatively large 858 859 (~ 59%) increase in the odds of pneumonia, reflecting the immense heterogeneity spanned within this region. Further analyses of the MHC signal are warranted, particularly to 860 861 deconvolve specific HLA types that may contribute to pneumonia susceptibility and 862 progression. Each of the loci beyond the MHC identified this study were relatively complex, 863 although we were able to derive a 95% credible set for the most significant non-MHC locus on 864 chromosome 11 that implicated the mucin gene MUC5AC. It should be noted that our finemapping approach is relatively biologically naïve as it assumes a single causal variant, and 865 866 thus, the involvement of other genes remains unclear. MUC5AC is an interesting candidate 867 given that it has been previously implicated in the pathogenesis of respiratory illness and the 868 role of mucins in physical defence against pathogens via mucociliary clearance⁵⁹. This heavily glycosylated protein is lowly expressed in normal respiratory epithelium, however, is 869 870 upregulated upon in response to perturbagens, such as viral infection 60,61 . We posit that 871 upregulation of MUC5AC may be deleterious in the context of pneumonia given recent 872 evidence that this protein can enhance airway inflammation induced by viral infection⁶², 873 although dissection of the mechanisms of variants in this locus are warranted, particularly given 874 the apparent discordant relationship of this signal we observed on the odds on asthma. 875 Interestingly, there are some preliminary data that suggests MUC5AC is upregulated in the 876 airway mucus of patients with severe COVID-19, although these studies were conducted using small sample sizes^{63,64}. There was also evidence of a more expansive polygenic signal amongst 877 878 mucin and beta-galactoside/N-acetylgalactosaminide genes in the termination of O-glycan 879 biosynthesis pathway, whereby sialic acid residues conjugated to mucins can terminate O-880 glycan biosynthesis⁶⁵. Interestingly, therapies specifically targeting mucin-linked O-

881 glycosylation are now under active development, including a recently proposed hexosamine 882 analog that demonstrated potent inhibition of O-glycan biosynthesis and downregulation of 883 neutrophil infiltration in rodents⁶⁶.

884

885 Drug repurposing is an attractive downstream application for GWAS, and we demonstrate its 886 potential utility for pneumonia through three distinct methods. Causal inference between 887 biochemical traits and pneumonia may provide repositioning opportunities along with a greater 888 understanding of pathological mechanisms in the disorder. For instance, we reveal evidence to 889 suggest a potential protective effect of HDL cholesterol and a deleterious impact of elevated 890 triglycerides on the odds of pneumonia. These data support observational data that lower baseline HDL and elevated triglycerides have risk-increasing properties for pneumonia^{67–69}, . 891 We emphasise that our data only provided weak to moderate support for a causal influence of 892 893 lipid abundance on pneumonia, and replicated, well-powered randomised controlled trials are 894 needed to definitively assess the suitability of lipid-modifying agents like statins. A key 895 limitation of proposing drug repurposing candidates for the phenotype as a singular entity is 896 that it ignores the inherent heterogeneity of pneumonia onset and clinical course. It has been 897 shown previously that individual genes supported by GWAS significantly increase the 898 likelihood of a candidate drug being successfully approved from the phase I stage ⁷⁰, however, 899 the relevance of more expansive association signals relating to biological networks for 900 precision medicine remains unclear As a result, we sought to implement an approach which 901 seeks to target drug repositioning opportunities to those with elevated genetic risk within 902 pathways relevant to the compound (PES, one of the prioritised pathways for the construction 903 of a PES was the *Bile acid metabolism* gene-set, further supporting the relevance of compounds 904 that modulate cholesterol. In the UKBB cohort, we demonstrated that these scores were distinct 905 from genome-wide PRS, and thus, may offer biological insights that were missed by using a 906 genome-wide score. For example, the Bile acid metabolism PES was positively correlated with 907 triglyceride levels, whilst this was not observed for PRS. We caution that one cannot draw a 908 causal inference from this relationship. In addition, the putative relationship between PES and 909 IgG response to antigens is biologically relevant both in terms of increased and decreased 910 antibody response. One can conceptualise the phenotype of pneumonia as having a contribution 911 from increased likelihood of infection, but also an aberrant inflammatory response once 912 infected with a pathogen. The distinct signal observed with these IgG phenotypes for the 913 pathway-based PES compared to genome-wide PRS, therefore, further highlights the potential 914 utility of the PES framework. Further work is required to evaluate the suitability of compounds

915 that modulate the PES pathways of interest and to categorise drug repurposing candidates based 916 on their suitability for prevention and/or treatment of pneumonia. The key advantage of the 917 PES framework is that only individuals with relevant genetic background in a pathway of 918 interest would be prioritised for the respective repurposing candidate, which would be useful 919 given the polygenic nature of complex disorders. Detailed discussion of the strengths and 920 limitations of the PES methodology have been featured in previous publications^{27,37}.

921

922 There are a number of important limitations that should be considered in light of the pneumonia 923 GWAS itself and our drug repurposing analyses. Firstly, this GWAS was conducted using 924 samples from European ancestry as large, diverse, genotyped cohorts with pneumonia status 925 information are not yet available. It will be critical to translate findings related to host-genetic 926 influences on pneumonia that future efforts strive to collect trans-ancestral data, particularly 927 due to concerns about the portability of European GWAS signals and the advantages in finemapping afforded by including multiple ancestries⁷¹. The SNP heritability for pneumonia 928 929 derived in this study was also relatively low, and it remains unclear how heterogeneity amongst 930 the phenotype definition of pneumonia may contribute to this. In other words, given that 931 pneumonia is caused by a variety of factors and may go undiagnosed in some individuals, 932 detailed phenotyping data would potentially assist in resolving the genetic architecture of this 933 disorder. For example, a GWAS on susceptibility verses pneumonia severity will likely reveal 934 different biological insights. This could also be aided by stratified analyses by age, given 935 pneumonia is more pervasive in the elderly. The putative drug repurposing candidates 936 suggested in this study must also be viewed in light of the low heritability of pneumonia and 937 need for clinical validation. Despite these challenges, we believe that further resolving the host-938 genetic architecture of pneumonia will be invaluable to public health efforts to more effectively 939 prevent and manage the illness. In summary, we revealed novel genome-wide significant loci 940 associated with life-time pneumonia susceptibility beyond the MHC region. These data 941 provided some support for the potential utility of triglycerides and GGT as treatment targets 942 for pneumonia, however, randomised controlled trials are now required to establish the efficacy 943 of such interventions. Moreover, the pharmagenic enrichment score approach may provide a 944 precision medicine-based intervention for drug repurposing for pneumonia prophylaxis and 945 treatment given an individual's composition of genetic risk. The properties of these scores and 946 the prospects of integrating them with other clinical metrics warrants further research.

- 947
- 948

949 **DECLARATION OF INTERESTS**

W.R.R and M.J.C have filed a patent related to the use of the pharmagenic enrichment score
framework in complex disorders, the remaining authors declare no competing financial
interests.

953

954 ACKNOWLEDGEMENTS

We wish to acknowledge the participants and investigators of FinnGen study and the 23andMe
Inc. study from which these data were derived for the GWAS meta-analysis. In addition, his
research has been conducted using the UK Biobank Resource under the application 58432.
This study was supported by an NHMRC project grant (1147644). M.J.C. is supported by an
NHMRC Senior Research Fellowship (1121474).

- 961 CONSORTIA
- 962

963 The 23andMe Research Team

- 964 Michelle Agee³, Babak Alipanahi³, Robert K. Bell³, Katarzyna Bryc³, Sarah L. Elson³, Pierre
- Fontanillas³, Nicholas A. Furlotte³, Barry Hicks³, David A. Hinds³, Karen E. Huber³, Ethan M.
 Jewett³, Yunxuan Jiang³, Aaron Kleinman³, Keng-Han Lin³, Nadia K. Litterman³, Jennifer C.
 McCreight³, Matthew H. McIntyre³, Kimberly F. McManus³, Joanna L. Mountain³, Elizabeth
 S. Noblin³, Carrie A. M Northover³, Steven J. Pitts³, G. David Poznik³, J. Fah
 Sathirapongsasuti³, Janie F. Shelton³, Suyash Shringarpure³, Chao Tian³, Joyce Y. Tung³,
 Vladimir Vacic³, Xin Wang³ & Catherine H. Wilson³.
- 971

972 AUTHOR INFORMATION

973

974 School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, The

975 University of Newcastle, Callaghan, NSW, 2308, Australia

- 976 William R. Reay, Michael P. Geaghan, and Murray J. Cairns
- 977

978 Hunter Medical Research Institute, Newcastle, NSW, 2305, Australia

- 979 William R. Reay, Michael P. Geaghan, and Murray J. Cairns
- 980

981 23andMe Inc., Sunnyvale, CA, 94086, United States of America

982 The 23andMe Research Team

983 WEB RESOURCES

- 984 DGIdb v4.2.0 https://www.dgidb.org/
- 985 FAVOR http://favor.genohub.org/
- 986 FOCUS version July 24 2019 https://github.com/bogdanlab/focus
- 987 FUMA v1.3.6 https://fuma.ctglab.nl/
- 988 FUSION version May 29 2020 https://github.com/gusevlab/fusion_twas
- 989 LCV version March 15 2019 https://github.com/lukejoconnor/LCV
- 990 LDSR v1.0.1 https://github.com/bulik/ldsc
- 991 MAGMA v.1.07b https://ctg.cncr.nl/software/magma
- 992 METAL version March 2011 https://genome.sph.umich.edu/wiki/METAL_Quick_Start
- 993 MR-PRESSO v1 https://github.com/rondolab/MR-PRESSO/commits/master
- 994 mtCOJO (GCTA version 1.93.2 beta mac) -
- 995 https://cnsgenomics.com/software/gcta/#mtCOJO
- 996 PLINK2 v.2.00a3LM https://www.cog-genomics.org/plink/2.0/
- 997 PRSice-2 v.2.3.3 (linux) https://www.prsice.info/
- 998 TwoSampleMR v.0.5.5 https://github.com/MRCIEU/TwoSampleMR
- 999 VEP GRCh37 release 101 August 2020 -
- 1000 https://grch37.ensembl.org/Homo sapiens/Tools/VEP?db=core
- 1001 WebGestaltR v.4.0.2 https://github.com/bzhanglab/WebGestaltR
- 1002
- 1003

1004 DATA AND CODE AVAILABILITY

- 1005 All data in this study are publicly available, summary statistics from 23andMe Inc. can be
- 1006 obtained upon application to the company. As per 23andMe data sharing policies, we are
- 1007 only able to release 10,000 SNPs from our meta-analysis, which we have made available on
- 1008 GitHub
- 1009 (https://github.com/Williamreay/Pneumonia_meta_GWAS_drug_repurposing/tree/master/Su
- 1010 <u>mmary statistics</u>). The full GWAS summary statistics for the 23andMe discovery data set
- 1011 will be made available through 23andMe to qualified researchers under an agreement with
- 1012 23andMe that protects the privacy of the 23andMe participants.
- 1013 Researchers wishing to recapitulate our meta-analysis can apply for access for the 23andMe
- 1014 subset of the study (https://research.23andme.com/dataset-access/), and then meta-analyse
- 1015 with FinnGen release 3 summary statistics as described in our manuscript. Code utilised in

- 1016 this study is available also on GitHub -
- 1017 https://github.com/Williamreay/Pneumonia meta GWAS drug repurposing.
- 1018
- 1019

1020 REFERENCES

- 1021 1. Mackenzie, G. (2016). The definition and classification of pneumonia. Pneumonia 1022 (Nathan) 8, 14.
- 1023 2. Restrepo, M.I., Faverio, P., and Anzueto, A. (2013). Long-term prognosis in community-1024 acquired pneumonia. Curr Opin Infect Dis 26, 151-158.
- 1025 3. McAllister, D.A., Liu, L., Shi, T., Chu, Y., Reed, C., Burrows, J., Adeloye, D., Rudan, I.,
- 1026 Black, R.E., Campbell, H., et al. (2019). Global, regional, and national estimates of
- 1027 pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: 1028 a systematic analysis. Lancet Glob Health 7, e47–e57.
- 1029 4. Obel, N., Christensen, K., Petersen, I., Sørensen, T.I.A., and Skytthe, A. (2010). Genetic 1030 and Environmental Influences on Risk of Death due to Infections Assessed in Danish Twins,
- 1031 1943–2001. American Journal of Epidemiology 171, 1007–1013.
- 1032 5. Tian, C., Hromatka, B.S., Kiefer, A.K., Eriksson, N., Noble, S.M., Tung, J.Y., and Hinds,
- 1033 D.A. (2017). Genome-wide association and HLA region fine-mapping studies identify 1034 susceptibility loci for multiple common infections. Nat Commun 8, 599.
- 1035 6. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis 1036 of genomewide association scans. Bioinformatics 26, 2190-2191.
- 1037 7. Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional 1038 mapping and annotation of genetic associations with FUMA. Nat Commun 8, 1826.
- 1039 8. Zhu, Z., Zheng, Z., Zhang, F., Wu, Y., Trzaskowski, M., Maier, R., Robinson, M.R.,
- 1040 McGrath, J.J., Visscher, P.M., Wray, N.R., et al. (2018). Causal associations between risk
- 1041 factors and common diseases inferred from GWAS summary data. Nat Commun 9, 224.
- 1042 9. Liu, M., Jiang, Y., Wedow, R., Li, Y., Brazel, D.M., Chen, F., Datta, G., Davila-
- 1043 Velderrain, J., McGuire, D., Tian, C., et al. (2019). Association studies of up to 1.2 million 1044 individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet 51, 237-244. 1045
- 1046 10. Ferreira, M.A.R., Mathur, R., Vonk, J.M., Szwajda, A., Brumpton, B., Granell, R., Brew, 1047 B.K., Ullemar, V., Lu, Y., Jiang, Y., et al. (2019). Genetic Architectures of Childhood- and
- 1048 Adult-Onset Asthma Are Partly Distinct. Am J Hum Genet 104, 665-684.
- 1049 11. Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace,
- 1050 C., and Plagnol, V. (2014). Bayesian test for colocalisation between pairs of genetic
- 1051 association studies using summary statistics. PLoS Genet. 10, e1004383.
- 1052 12. Zhou, W., Nielsen, J.B., Fritsche, L.G., Dey, R., Gabrielsen, M.E., Wolford, B.N.,
- 1053 LeFaive, J., VandeHaar, P., Gagliano, S.A., Gifford, A., et al. (2018). Efficiently controlling

- 1054 for case-control imbalance and sample relatedness in large-scale genetic association studies. 1055 Nat. Genet. 50, 1335-1341.
- 1056 13. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.-R.,
- 1057 ReproGen Consortium, Psychiatric Genomics Consortium, Genetic Consortium for Anorexia
- 1058 Nervosa of the Wellcome Trust Case Control Consortium 3, Duncan, L., et al. (2015). An 1059 atlas of genetic correlations across human diseases and traits. Nat. Genet. 47, 1236–1241.
- 1060 14. Wellcome Trust Case Control Consortium, Maller, J.B., McVean, G., Byrnes, J.,
- 1061 Vukcevic, D., Palin, K., Su, Z., Howson, J.M.M., Auton, A., Myers, S., et al. (2012). 1062 Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat. Genet. 44,
- 1063 1294-1301.
- 1064 15. Benner, C., Havulinna, A.S., Järvelin, M.-R., Salomaa, V., Ripatti, S., and Pirinen, M.
- 1065 (2017). Prospects of Fine-Mapping Trait-Associated Genomic Regions by Using Summary
- 1066 Statistics from Genome-wide Association Studies. Am J Hum Genet 101, 539–551.
- 1067 16. de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA: 1068 generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11, e1004219.
- 1069 17. Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J.P., and Tamayo, P.
- 1070 (2015). The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell 1071 Syst 1, 417–425.
- 18. Liu, Y., and Xie, J. (2020). Cauchy Combination Test: A Powerful Test With Analytic p -1072
- 1073 Value Calculation Under Arbitrary Dependency Structures. Journal of the American 1074 Statistical Association 115, 393-402.
- 1075 19. Liu, Y., Chen, S., Li, Z., Morrison, A.C., Boerwinkle, E., and Lin, X. (2019). ACAT: A
- 1076 Fast and Powerful p Value Combination Method for Rare-Variant Analysis in Sequencing
- 1077 Studies. Am. J. Hum. Genet. 104, 410-421.
- 1078 20. Turkmen, A., and Lin, S. (2017). Are rare variants really independent? Genet. Epidemiol. 1079 41, 363-371.
- 1080 21. Talluri, R., and Shete, S. (2013). A linkage disequilibrium-based approach to selecting 1081 disease-associated rare variants. PLoS ONE 8, e69226.
- 1082 22. Gusev, A., Ko, A., Shi, H., Bhatia, G., Chung, W., Penninx, B.W.J.H., Jansen, R., de 1083 Geus, E.J.C., Boomsma, D.I., Wright, F.A., et al. (2016). Integrative approaches for large-
- 1084 scale transcriptome-wide association studies. Nat. Genet. 48, 245–252.
- 1085 23. Mancuso, N., Freund, M.K., Johnson, R., Shi, H., Kichaev, G., Gusev, A., and Pasaniuc, 1086 B. (2019). Probabilistic fine-mapping of transcriptome-wide association studies. Nat. Genet. 1087 51, 675–682.
- 1088 24. Zheng, J., Erzurumluoglu, A.M., Elsworth, B.L., Kemp, J.P., Howe, L., Haycock, P.C.,
- 1089 Hemani, G., Tansey, K., Laurin, C., Early Genetics and Lifecourse Epidemiology (EAGLE)
- 1090 Eczema Consortium, et al. (2017). LD Hub: a centralized database and web interface to
- 1091 perform LD score regression that maximizes the potential of summary level GWAS data for
- 1092 SNP heritability and genetic correlation analysis. Bioinformatics 33, 272–279.

- 1093 25. O'Connor, L.J., and Price, A.L. (2018). Distinguishing genetic correlation from causation 1094 across 52 diseases and complex traits. Nat. Genet. *50*, 1728–1734.
- 1095 26. Reay, W.R., Kiltschewskij, D.J., Geaghan, M.P., Atkins, J.R., Carr, V.J., Green, M.J., and
- Cairns, M.J. (2021). Genetic estimates of correlation and causality between blood-based
 biomarkers and psychiatric disorders (Psychiatry and Clinical Psychology).
- 1098 27. Reay, W.R., El Shair, S.I., Geaghan, M.P., Riveros, C., Holliday, E.G., McEvoy, M.A.,
- 1099 Hancock, S., Peel, R., Scott, R.J., Attia, J.R., et al. (2021). Genetic association and causal
- inference converge on hyperglycaemia as a modifiable factor to improve lung function. ELife*10*, e63115.
- 1102 28. Hemani, G., Zheng, J., Elsworth, B., Wade, K.H., Haberland, V., Baird, D., Laurin, C.,
- 1103 Burgess, S., Bowden, J., Langdon, R., et al. (2018). The MR-Base platform supports
- 1104 systematic causal inference across the human phenome. ELife 7, e34408.
- 1105 29. Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M., Gustafsson, S., Kanoni, S.,
- 1106 Ganna, A., Chen, J., Buchkovich, M.L., Mora, S., et al. (2013). Discovery and refinement of
- 1107 loci associated with lipid levels. Nat Genet 45, 1274–1283.
- 1108 30. Bowden, J., Davey Smith, G., Haycock, P.C., and Burgess, S. (2016). Consistent
- 1109 Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted
- 1110 Median Estimator. Genet. Epidemiol. 40, 304–314.
- 1111 31. Hartwig, F.P., Davey Smith, G., and Bowden, J. (2017). Robust inference in summary
- data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 46,1113 1985–1998.
- 1114 32. Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian randomization with
- 1115 invalid instruments: effect estimation and bias detection through Egger regression. Int J
- 1116 Epidemiol 44, 512–525.
- 1117 33. Verbanck, M., Chen, C.-Y., Neale, B., and Do, R. (2018). Detection of widespread
- horizontal pleiotropy in causal relationships inferred from Mendelian randomization between
 complex traits and diseases. Nat. Genet. 50, 693–698.
- 34. Thompson, S.G., and Sharp, S.J. (1999). Explaining heterogeneity in meta-analysis: acomparison of methods. Stat Med *18*, 2693–2708.
- 1122 35. Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N., and Thompson,
- J. (2017). A framework for the investigation of pleiotropy in two-sample summary data
 Mendelian randomization. Stat Med *36*, 1783–1802.
- 1125 36. Reay, W.R., Shair, S.E., Geaghan, M.P., Riveros, C., Holiday, E.G., McEvoy, M.A.,
- 1126 Hancock, S., Peel, R., Scott, R.J., Attia, J.R., et al. (2020). Genetically informed precision
- 1127 drug repurposing for lung function and implications for respiratory infection (Respiratory
- 1128 Medicine).
- 1129 37. Reay, W.R., Atkins, J.R., Carr, V.J., Green, M.J., and Cairns, M.J. (2020).
- 1130 Pharmacological enrichment of polygenic risk for precision medicine in complex disorders.
- 1131 Sci Rep 10, 879.

- 1132 38. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott,
- 1133 P., Green, J., Landray, M., et al. (2015). UK biobank: an open access resource for identifying
- the causes of a wide range of complex diseases of middle and old age. PLoS Med *12*,
- 1135 e1001779.
- 1136 39. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A.,
- 1137 Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep 1138 phenotyping and genomic data. Nature *562*, 203–209.
- 40. Choi, S.W., and O'Reilly, P.F. (2019). PRSice-2: Polygenic Risk Score software forbiobank-scale data. GigaScience 8, giz082.
- 1141 41. Mentzer, A.J., Brenner, N., Allen, N., Littlejohns, T.J., Chong, A.Y., Cortes, A., Almond,
- 1142 R., Hill, M., Sheard, S., McVean, G., et al. (2019). Identification of host-pathogen-disease
- 1143 relationships using a scalable Multiplex Serology platform in UK Biobank (Infectious1144 Diseases (except HIV/AIDS)).
- 1145 42. Gu, Z., Eils, R., and Schlesner, M. (2016). Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics *32*, 2847–2849.
- 1147 43. Linden, S.K., Sutton, P., Karlsson, N.G., Korolik, V., and McGuckin, M.A. (2008).
- 1148 Mucins in the mucosal barrier to infection. Mucosal Immunol 1, 183–197.
- 1149 44. Chen, H.-H., Shaw, D.M., Petty, L.E., Graff, M., Bohlender, R.J., Polikowsky, H.G.,
- 1150 Zhong, X., Kim, D., Buchanan, V.L., Preuss, M.H., et al. (2021). Host genetic effects in
- 1151 pneumonia. The American Journal of Human Genetics *108*, 194–201.
- 1152 45. Campos, A.I., Kho, P.F., Vazquez-Prada, K.X., García-Marín, L.M., Martin, N.G.,
- 1153 Cuéllar-Partida, G., and Rentería, M.E. (2020). Genetic susceptibility to pneumonia: A
- 1154 GWAS meta-analysis between UK Biobank and FinnGen (Respiratory Medicine).
- 1155 46. Kim, K., Park, S., Park, S.Y., Kim, G., Park, S.M., Cho, J.-W., Kim, D.H., Park, Y.M.,
- 1156 Koh, Y.W., Kim, H.R., et al. (2020). Single-cell transcriptome analysis reveals TOX as a
- 1157 promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human
- 1158 cancer. Genome Med 12, 22.
- 1159 47. Sekine, T., Perez-Potti, A., Nguyen, S., Gorin, J.-B., Wu, V.H., Gostick, E., Llewellyn-
- 1160 Lacey, S., Hammer, Q., Falck-Jones, S., Vangeti, S., et al. (2020). TOX is expressed by
- 1161 exhausted and polyfunctional human effector memory CD8 ⁺ T cells. Sci. Immunol. 5,
- 1162 eaba7918.
- 1163 48. Lin, C.-L., Liu, T.-C., Chung, C.-H., and Chien, W.-C. (2018). Risk of pneumonia in
- 1164 patients with insomnia: A nationwide population-based retrospective cohort study. J Infect
- 1165 Public Health 11, 270–274.
- 49. Patel, S.R., Malhotra, A., Gao, X., Hu, F.B., Neuman, M.I., and Fawzi, W.W. (2012). A
 prospective study of sleep duration and pneumonia risk in women. Sleep *35*, 97–101.
- 50. Burgess, S., and Thompson, S.G. (2015). Multivariable Mendelian randomization: the use
 of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol *181*, 251–260.

- 1170 51. Parr, J.B. (2020). Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia. JAMA1171 Intern Med.
- 1172 52. Folkersen, L., Fauman, E., Sabater-Lleal, M., Strawbridge, R.J., Frånberg, M., Sennblad,
- 1173 B., Baldassarre, D., Veglia, F., Humphries, S.E., Rauramaa, R., et al. (2017). Mapping of 79
- 1174 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet *13*, e1006706.
- 1175 53. Ferreira, R.C., Freitag, D.F., Cutler, A.J., Howson, J.M.M., Rainbow, D.B., Smyth, D.J.,
- 1176 Kaptoge, S., Clarke, P., Boreham, C., Coulson, R.M., et al. (2013). Functional IL6R 358Ala
- allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory
- 1178 diseases. PLoS Genet 9, e1003444.
- 1179 54. Davis, W.A., Knuiman, M., Kendall, P., Grange, V., Davis, T.M.E., and Fremantle
- 1180 Diabetes Study (2004). Glycemic exposure is associated with reduced pulmonary function in
- 1181 type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 27, 752–757.
- 1182 55. King, J.B., West, M.B., Cook, P.F., and Hanigan, M.H. (2009). A novel, species-specific
- 1183 class of uncompetitive inhibitors of gamma-glutamyl transpeptidase. J Biol Chem 284, 9059–
- 1184 *9065*.
- 1185 56. Tuzova, M., Jean, J.-C., Hughey, R.P., Brown, L.A.S., Cruikshank, W.W., Hiratake, J.,
- and Joyce-Brady, M. (2014). Inhibiting lung lining fluid glutathione metabolism with
- 1187 GGsTop as a novel treatment for asthma. Front Pharmacol 5, 179.
- 1188 57. Smailhodzic, D., van Asten, F., Blom, A.M., Mohlin, F.C., den Hollander, A.I., van de
- 1189 Ven, J.P.H., van Huet, R.A.C., Groenewoud, J.M.M., Tian, Y., Berendschot, T.T.J.M., et al.
- 1190 (2014). Zinc Supplementation Inhibits Complement Activation in Age-Related Macular
- 1191 Degeneration. PLoS ONE 9, e112682.
- 1192 58. Nan, R., Tetchner, S., Rodriguez, E., Pao, P.-J., Gor, J., Lengyel, I., and Perkins, S.J.
- 1193 (2013). Zinc-induced self-association of complement C3b and Factor H: implications for
- 1194 inflammation and age-related macular degeneration. J Biol Chem 288, 19197–19210.
- 59. Bustamante-Marin, X.M., and Ostrowski, L.E. (2017). Cilia and Mucociliary Clearance.
 Cold Spring Harb Perspect Biol 9,.
- 1197 60. Hewson, C.A., Haas, J.J., Bartlett, N.W., Message, S.D., Laza-Stanca, V., Kebadze, T.,
- 1198 Caramori, G., Zhu, J., Edbrooke, M.R., Stanciu, L.A., et al. (2010). Rhinovirus induces
- 1199 MUC5AC in a human infection model and in vitro via NF-κB and EGFR pathways. Eur
- 1200 Respir J *36*, 1425–1435.
- 61. Barbier, D., Garcia-Verdugo, I., Pothlichet, J., Khazen, R., Descamps, D., Rousseau, K.,
 Thornton, D., Si-Tahar, M., Touqui, L., Chignard, M., et al. (2012). Influenza A induces the
 major secreted airway mucin MUC5AC in a protease-EGFR-extracellular regulated kinase-
- 1204 Sp1-dependent pathway. Am J Respir Cell Mol Biol 47, 149–157.
- 1205 62. Singanayagam, A., Footitt, J., Kasdorf, B.T., Marczynski, M., Cross, M.T., Finney, L.J.,
- 1206 Trujillo Torralbo, M.-B., Calderazzo, M., Zhu, J., Aniscenko, J., et al. (2019). MUC5AC
- 1207 drives COPD exacerbation severity through amplification of virus-induced airway
- 1208 inflammation (Immunology).

- 1209 63. Lu, W., Liu, X., Wang, T., Liu, F., Zhu, A., Lin, Y., Luo, J., Ye, F., He, J., Zhao, J., et al.
- 1210 (2020). Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill 1211 COVID-19 patients. I Med Virol
- 1211 COVID-19 patients. J Med Virol.
- 1212 64. He, J., Cai, S., Feng, H., Cai, B., Lin, L., Mai, Y., Fan, Y., Zhu, A., Huang, H., Shi, J., et
- al. (2020). Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19
 patients. Protein Cell 11, 680–687.
- 1215 65. (2009). Essentials of Glycobiology (Cold Spring Harbor (NY): Cold Spring Harbor1216 Laboratory Press).
- 1217 66. Wang, S.-S., del Solar, V., Yu, X., Antonopoulos, A., Friedman, A.E., Agarwal, K., Garg,
- 1218 M., Ahmed, S.M., Addya, A., Nasirikenari, M., et al. (2020). Efficient Inhibition of O-glycan
- 1219 biosynthesis using the hexosamine analog Ac 5 GalNTGc (Biochemistry).
- 1220 67. Bae, S.S., Chang, L.C., Merkin, S.S., Elashoff, D., Ishigami, J., Matsushita, K., and
- 1221 Charles-Schoeman, C. (2020). Major Lipids and Future Risk of Pneumonia: 20-Year
- 1222 Observation of the Atherosclerosis Risk in Communities (ARIC) Study Cohort. The
- 1223 American Journal of Medicine S0002934320306987.
- 1224 68. Chien, Y.-F., Chen, C.-Y., Hsu, C.-L., Chen, K.-Y., and Yu, C.-J. (2015). Decreased
- serum level of lipoprotein cholesterol is a poor prognostic factor for patients with severe
- 1226 community-acquired pneumonia that required intensive care unit admission. J Crit Care 30,1227 506–510.
- 1228 69. Antcliffe, D., Jiménez, B., Veselkov, K., Holmes, E., and Gordon, A.C. (2017).
- 1229 Metabolic Profiling in Patients with Pneumonia on Intensive Care. EBioMedicine *18*, 244– 1230 253.
- 70. Nelson, M.R., Tipney, H., Painter, J.L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A.,
 Sham, P.C., Li, M.J., Wang, J., et al. (2015). The support of human genetic evidence for
- 1233 approved drug indications. Nat Genet 47, 856–860.
- 1234 71. Asimit, J.L., Hatzikotoulas, K., McCarthy, M., Morris, A.P., and Zeggini, E. (2016).
 1235 Trans-ethnic study design approaches for fine-mapping. Eur J Hum Genet 24, 1330–1336.
- 1236

1237

1238